SOURCE: NexMed, Inc.

March 16, 2006 09:03 ET

NexMed to Release 2005 Financial Results and Host Conference Call on Friday, March 17, 2006

EAST WINDSOR, NJ -- (MARKET WIRE) -- March 16, 2006 -- NexMed, Inc. (NASDAQ: NEXM), a developer of innovative pharmaceutical products based on its proprietary NexACT® transdermal drug delivery technology, announced that the Company intends to file its Form 10-K for year ended December 31, 2005 today. Management will host a conference call tomorrow, Friday, March 17, 2006 at 9:00a.m. (EST) to discuss these results and to provide a Company update.

The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054, and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 196183 are both required for playback. The conference call will also be Webcast live at URL

2005 Highlights

--  NexMed announced a global licensing agreement for its topical
    proprietary treatment for nail fungus.  The current market for this
    therapeutic indication is over $1 billion worldwide, with two oral
    medications currently dominating the market.
--  NexMed significantly streamlined its operations and successfully
    reduced its burn rate by approximately half, or to about $550,000 per
--  NexMed announced positive results from a large "at home" study of the
    Femprox® cream in 400 pre-menopausal and post-menopausal women diagnosed
    with female sexual arousal disorder.  The multi-center study which was
    conducted in China, was randomized, double-blind, placebo-controlled, and
    designed to investigate the efficacy and safety of three strengths of the
About NexMed, Inc.

NexMed, an innovative drug developer, offers large pharmaceutical companies the opportunity to save considerably on R&D costs, develop new patient-friendly transdermal products, and extend patent lifespans and brand equity, through participation in early stage licensing and development partnerships. NexMed currently has a host of medicines in development, such as treatments for nail fungus, sexual disorders and more, all based on its proprietary NexACT drug delivery technology.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to its ability to effectively reduce expenses, enter into partnering agreements, raise financing on acceptable terms, pursue growth opportunities, and/or other factors, some of which are outside the control of the Company.

Contact Information

  • Contact:
    Deborah Carty
    NexMed, Inc.
    (609) 371-9688, ext: 159
    Email Contact